439 related articles for article (PubMed ID: 30746734)
1. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.
Arnst KE; Banerjee S; Chen H; Deng S; Hwang DJ; Li W; Miller DD
Med Res Rev; 2019 Jul; 39(4):1398-1426. PubMed ID: 30746734
[TBL] [Abstract][Full Text] [Related]
2. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
3. The Potential Strategies for Overcoming Multidrug Resistance and Reducing Side Effects of Monomer Tubulin Inhibitors for Cancer Therapy.
Cui Y; Zhang J; Zhang G
Curr Med Chem; 2024; 31(14):1874-1895. PubMed ID: 37349994
[TBL] [Abstract][Full Text] [Related]
4. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
Perez EA
Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
[TBL] [Abstract][Full Text] [Related]
5. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
Field JJ; Kanakkanthara A; Miller JH
Bioorg Med Chem; 2014 Sep; 22(18):5050-9. PubMed ID: 24650703
[TBL] [Abstract][Full Text] [Related]
6. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
7. Development of novel derivatives of stilbene and macrocyclic compounds as potent of anti-microtubule factors.
Borys F; Tobiasz P; Poterała M; Krawczyk H
Biomed Pharmacother; 2021 Jan; 133():110973. PubMed ID: 33378993
[TBL] [Abstract][Full Text] [Related]
8. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.
Liaw TY; Chang MH; Kavallaris M
Curr Drug Targets; 2007 Jun; 8(6):739-49. PubMed ID: 17584029
[TBL] [Abstract][Full Text] [Related]
9. Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy.
Shuai W; Wang G; Zhang Y; Bu F; Zhang S; Miller DD; Li W; Ouyang L; Wang Y
J Med Chem; 2021 Jun; 64(12):7963-7990. PubMed ID: 34101463
[TBL] [Abstract][Full Text] [Related]
10. Revisiting microtubule targeting agents: α-Tubulin and the pironetin binding site as unexplored targets for cancer therapeutics.
Coulup SK; Georg GI
Bioorg Med Chem Lett; 2019 Aug; 29(15):1865-1873. PubMed ID: 31130264
[TBL] [Abstract][Full Text] [Related]
11. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
Fürst R; Vollmar AM
Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
[TBL] [Abstract][Full Text] [Related]
12. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
Kanakkanthara A; Teesdale-Spittle PH; Miller JH
Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
[TBL] [Abstract][Full Text] [Related]
13. [Progress in the study of tubulin inhibitors].
Shang H; Pan L; Yang S; Chen H; Cheng MS
Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
[TBL] [Abstract][Full Text] [Related]
14. Towards modern anticancer agents that interact with tubulin.
La Regina G; Coluccia A; Naccarato V; Silvestri R
Eur J Pharm Sci; 2019 Apr; 131():58-68. PubMed ID: 30690185
[TBL] [Abstract][Full Text] [Related]
15. Targeting microtubules for cancer chemotherapy.
Zhou J; Giannakakou P
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
[TBL] [Abstract][Full Text] [Related]
16. Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors.
Hoque M; Abbassi RH; Froio D; Man J; Johns TG; Stringer BW; Day BW; Pajic M; Kassiou M; Munoz L
Pharmacol Res; 2018 Aug; 134():166-178. PubMed ID: 29944980
[TBL] [Abstract][Full Text] [Related]
17. Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018).
Haider K; Rahaman S; Yar MS; Kamal A
Expert Opin Ther Pat; 2019 Aug; 29(8):623-641. PubMed ID: 31353978
[No Abstract] [Full Text] [Related]
18. Microtubule destabilising agents: far more than just antimitotic anticancer drugs.
Bates D; Eastman A
Br J Clin Pharmacol; 2017 Feb; 83(2):255-268. PubMed ID: 27620987
[TBL] [Abstract][Full Text] [Related]
19. Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy.
Danziger M; Noble H; Roque DM; Xu F; Rao GG; Santin AD
Adv Exp Med Biol; 2024; 1452():1-19. PubMed ID: 38805122
[TBL] [Abstract][Full Text] [Related]
20. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
